[1]Cheng Q, Ding H, Fang J, et al. Aquaporin 9 represents a novel target of chronic liver injury that may antagonize its progression by reducing lipotoxicity[J]. Oxid Med Cell Longev, 2021, 2021(10): 5653700.
[2]Cheng Q, Zhang J, Fang J, et al. Untargeted metabolomics reveals the role of AQP9 in nonalcoholic fatty liver disease in a mice model[J]. Int J Biol Macromol, 2022, 219(10): 864-875.
[3]Yu W, Hill WG. Lack of specificity shown by P2Y6 receptor antibodies[J]. Naunyn Schmiedebergs Arch Pharmacol, 2013, 386(10): 885-891.
[4]Hall B, Limaye A, Kulkarni AB. Overview: generation of gene knockout mice[J]. Curr Protoc Cell Biol, 2009, 19(12): 11-17.
[5]Morinaga T, Nakakoshi M, Hirao A, et al. Mouse aquaporin 10 gene (AQP10) is a pseudogene[J]. Biochem Biophys Res Commun, 2002,294(3): 630-634.
[6]Ishibashi K, Tanaka Y, Morishita Y. The role of mammalian superaquaporins inside the cell: An update[J]. Biochim Biophys Acta Biomembr,2021, 1863(7): 183617.
[7]Hara-Chikuma M, Tanaka M, Verkman AS, et al. Inhibition of aquaporin-3 in macrophages by a monoclonal antibody as potential therapy for liver injury[J]. Nat Commun, 2020,11(1): 5666.
|